Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.
Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.
Transcript
What is the landscape like for patients trying to get coverage for atypical antipsychotis that cause fewer metabolic side effects?
We do have choices in terms of the array of antipsychotics that are available for the treatment of schizophrenia. Some may be more metabolically friendly than others. But they tend to be branded products, and so more costly. But it's not usually an impossibility to get them for our patients. I don't see huge obstacles in prescribing branded, atypical antipsychotics where they would be needed.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More